Article Details

PhaseBio Pharmaceuticals (PHAS) Downgraded by Zacks Investment Research to Sell

Retrieved on: 2019-05-23 22:37:30

Tags for this article:

Click the tags to see associated articles and topics

PhaseBio Pharmaceuticals (PHAS) Downgraded by Zacks Investment Research to Sell. View article details on hiswai:

Excerpt

<div><b>Schonfeld Strategic Advisors</b> LLC acquired a new position in PhaseBio Pharmaceuticals during the first quarter worth $600,000. Finally, Wellington ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up